JAK2 and acute lymphoblastic leukemia: SJ10542 was demonstrated to be efficacious in patient-derived ALL cells that exhibited JAK2 fusions (for JAK2: DC50 = 14 nM and Dmax = 90%: for JAK3: DC50 = 11 nM and Dmax = 92%) and CRLF2 rearrangements.